In 220 memory clinic outpatients with SCD, MCI or mild dementia, earlier disclosure of plasma p-tau217 and NfL raised very high-confidence aetiological diagnosis at 3 months versus delayed disclosure (50.0% vs 4.6%), without worse emotional outcomes.
RCTn = 220
Estragués-Gázquez et al. Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Randomized Clinical Trial